117 related articles for article (PubMed ID: 9384532)
1. A closer view of an oncoprotein-tumor suppressor interaction.
Shair MD
Chem Biol; 1997 Nov; 4(11):791-4. PubMed ID: 9384532
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.
Chène P
Mol Cancer Res; 2004 Jan; 2(1):20-8. PubMed ID: 14757842
[TBL] [Abstract][Full Text] [Related]
3. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53.
Stoll R; Renner C; Hansen S; Palme S; Klein C; Belling A; Zeslawski W; Kamionka M; Rehm T; Mühlhahn P; Schumacher R; Hesse F; Kaluza B; Voelter W; Engh RA; Holak TA
Biochemistry; 2001 Jan; 40(2):336-44. PubMed ID: 11148027
[TBL] [Abstract][Full Text] [Related]
4. Sequence-specific 1H, 15N, and 13C assignment of the N-terminal domain of the human oncoprotein MDM2 that binds to p53.
Stoll R; Renner C; Mühlhahn P; Hansen S; Schumacher R; Hesse F; Kaluza B; Engh RA; Voelter W; Holak TA
J Biomol NMR; 2000 May; 17(1):91-2. PubMed ID: 10909873
[No Abstract] [Full Text] [Related]
5. Small molecule inhibitors of p53/MDM2 interaction.
Fotouhi N; Graves B
Curr Top Med Chem; 2005; 5(2):159-65. PubMed ID: 15853644
[TBL] [Abstract][Full Text] [Related]
6. Mdm2: keeping p53 under control.
Piette J; Neel H; Maréchal V
Oncogene; 1997 Aug; 15(9):1001-10. PubMed ID: 9285554
[TBL] [Abstract][Full Text] [Related]
7. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
8. The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics.
Zheleva DI; Lane DP; Fischer PM
Mini Rev Med Chem; 2003 May; 3(3):257-70. PubMed ID: 12698949
[TBL] [Abstract][Full Text] [Related]
9. A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors.
Chen R; Zhou J; Qin L; Chen Y; Huang Y; Liu H; Su Z
Biochemistry; 2017 Jun; 56(25):3273-3282. PubMed ID: 28581721
[TBL] [Abstract][Full Text] [Related]
10. Abundant expression of spliced HDM2 in Hodgkin lymphoma cells does not interfere with p14(ARF) and p53 binding.
Stürzenhofecker B; Schlott T; Quentin T; Kube D; Jung W; Trümper L
Leuk Lymphoma; 2003 Sep; 44(9):1587-96. PubMed ID: 14565663
[TBL] [Abstract][Full Text] [Related]
11. Small molecule antagonists of the MDM2 oncoprotein as anticancer agents.
Buolamwini JK; Addo J; Kamath S; Patil S; Mason D; Ores M
Curr Cancer Drug Targets; 2005 Feb; 5(1):57-68. PubMed ID: 15720190
[TBL] [Abstract][Full Text] [Related]
12. Use of a retroinverso p53 peptide as an inhibitor of MDM2.
Sakurai K; Chung HS; Kahne D
J Am Chem Soc; 2004 Dec; 126(50):16288-9. PubMed ID: 15600307
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanism of the interaction between MDM2 and p53.
Schon O; Friedler A; Bycroft M; Freund SM; Fersht AR
J Mol Biol; 2002 Oct; 323(3):491-501. PubMed ID: 12381304
[TBL] [Abstract][Full Text] [Related]
14. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo.
Böttger A; Böttger V; Sparks A; Liu WL; Howard SF; Lane DP
Curr Biol; 1997 Nov; 7(11):860-9. PubMed ID: 9382809
[TBL] [Abstract][Full Text] [Related]
15. Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation.
McCoy MA; Gesell JJ; Senior MM; Wyss DF
Proc Natl Acad Sci U S A; 2003 Feb; 100(4):1645-8. PubMed ID: 12552135
[TBL] [Abstract][Full Text] [Related]
16. MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation.
Wang C; Ivanov A; Chen L; Fredericks WJ; Seto E; Rauscher FJ; Chen J
EMBO J; 2005 Sep; 24(18):3279-90. PubMed ID: 16107876
[TBL] [Abstract][Full Text] [Related]
17. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
[TBL] [Abstract][Full Text] [Related]
18. Mdm2 inhibits the apoptotic function of p53 mainly by targeting it for degradation.
Yap DB; Hsieh JK; Lu X
J Biol Chem; 2000 Nov; 275(47):37296-302. PubMed ID: 10980197
[TBL] [Abstract][Full Text] [Related]
19. MDM2 oncogene as a novel target for human cancer therapy.
Zhang ; Wang H
Curr Pharm Des; 2000 Mar; 6(4):393-416. PubMed ID: 10788589
[TBL] [Abstract][Full Text] [Related]
20. Mdm2 promotes the rapid degradation of p53.
Haupt Y; Maya R; Kazaz A; Oren M
Nature; 1997 May; 387(6630):296-9. PubMed ID: 9153395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
